Article Text

other Versions

PDF
Retinoblastoma in Iran: outcomes in terms of patients survival and globe survival
  1. Masood Naseripour (masoodnp{at}yahoo.com),
  2. Hossein Nazari (h01nazari{at}yahoo.com),
  3. Pejman Bakhtiari (pejmanbakhtiari{at}yahoo.com),
  4. Mehdi Modarres-zadeh (mmodarres51{at}yahoo.com),
  5. Parvaneh Vosough,
  6. Mohammadreza Ansari (dr_mohammadrezaansari{at}yahoo.com)
  1. Eye Research Center, Iran University of Medical Sciences, Iran, Islamic Republic of
  2. Eye Research Center, Iran University of Medical Sciences, Iran, Islamic Republic of
  3. Eye Research Center, Iran University of Medical Sciences, Iran, Islamic Republic of
  4. Eye Research Center, Iran University of Medical Sciences, Iran, Islamic Republic of
  5. Ali-Asghar Hospital, Iran University of Medical Sciences, Iran, Islamic Republic of
  6. Kermanshah University of Medical Sciences, Iran, Islamic Republic of

    Abstract

    Background/aims: Retinoblastoma is a highly malignant eye tumor in children with different survival rates across the world. The aims of this study are to determine the globe and patient survival in children with retinoblastoma in a major referral center in Iran.

    Methods: 156 eyes of 105 consecutive patients with retinoblastoma were enrolled from 2001 to 2007. All demographic data, family history, presenting symptoms, duration of symptoms, ocular findings and treatment modalities that were used for the patients were collected. For patient survival, event was defined as death and for globe survival as enucleation.

    Results: Mean age at diagnosis was 28.5 months (unilateral 27.4 months; bilateral 30 months). Five patients had positive family history. Fifty two percent of the cases were unilateral and 48% of them were bilateral. The most common presenting sign was leukocoria (64.8 %) followed by strabismus (28.2%). Enucleation was done primarily for 75.9% of unilateral cases and 34.3% of bilateral cases. Secondary enucleation was necessary in 5.6% and 7.8% of unilateral and bilaterally involved eyes respectively. Sixty nine (44.2%) of 156 eyes were salvaged by different globe preserving modalities (unilateral, 18.5%; bilateral 57.9%). Kaplan-Meier survival estimate for globe preservation according to International Classification of Retinoblastoma (ICRB) was 100% for group A eyes, 93.5% for group B, 86.7% for group C, 57.1% for group D and 0% for group E eyes. Kaplan-Meier estimates for patients survival was 100% at one year, 94.8% at 3 years and 83.1% at 5 years.

    Conclusion: Progress in methods of treatment, early detection of the diseases and prompt referral to specialized centers have led to improved outcomes for patients with retinoblastoma in terms of globe and patients’ survival rates even in developing countries.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.